2025 Q4 -tulosraportti
Vain PDF
101 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
2 t sitten · MuokattuCEO Statement: The circVec technology is uniquely positioned with clear differentiation and no direct competitors and will serve as Circio’s platform engine to build and develop enhanced and safer gene and cell therapy medications, both in house and through partnerships. About: Circio is the global leader in vector-based circRNA expression systems with no known competitors with comparable versatility and performance. Circio.com- ·8 t sittenInsider trades in Circio 2026. The entire management and board have faith. See attachment.
·14 t sitten · MuokattuAvenue Biosciences confirms the collaboration and has made it part of their own strategy Avenue Biosciences has now presented the Circio collaboration on their own website and refers to it as a central project. At the same time, they highlight their recent capital raise of USD 5.7 million, which will be used to scale up their protein engineering platform. Early research collaborations are often announced by only one company. Here we see that both parties actively profile the collaboration, which increases the credibility that both see a real strategic value. This does not change the probability of success in itself, but it strengthens the impression that the collaboration is more than a symbolic press release. https://www.avenuebiosciences.com/press-release/circio-and-avenue-biosciences-jointly-announce-research-collaboration-to-enhance-protein-secretion-for-gene-therapy
·1 päivä sittenTHE CALENDAR TOWARDS NEW YEAR — MY READING. 📅🧬 No one knows the dates. But see what's actually in the cards: August 31st — Half-year report. Confirmed date. Full status on pipeline and how the 620 million are used. R&D updates often come here. 📊 September–November — five international conferences in a row. Shanghai, Boston, Phoenix, Hamburg, Cologne. Historically, conferences have been where Circio has presented new data. 🌍 And the milestones themselves, directly from the pipeline — all marked 2H 2026: 🫀 Heart: efficacy data in disease model (first step from reporter gene to real disease) 🧠 CNS: in vivo data from the top-5 collaboration 🧬 In vivo CAR-T: delivery + CAR expression My own guess on the order? The half-year report gives status and direction. The conferences this autumn are natural windows for data. And the CNS reading — the most important of all — points towards Q3/Q4. 🎯 But be clear with yourself: this is MY reading, not a schedule anyone has promised. Biotech slips. Data takes time. It can come later than this. 📉 It can also come faster. No one rings a bell first — remember that the in vivo confirmation in April came on a completely ordinary Friday, without warning. The point is not the date. The point is that the window is open now — and that several independent tracks are maturing into the same period. We know what we own. ♟️🧱🍷
1 päivä sittenWhat a week. Time for a couple beers 🍻😊
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
101 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 t sitten · MuokattuCEO Statement: The circVec technology is uniquely positioned with clear differentiation and no direct competitors and will serve as Circio’s platform engine to build and develop enhanced and safer gene and cell therapy medications, both in house and through partnerships. About: Circio is the global leader in vector-based circRNA expression systems with no known competitors with comparable versatility and performance. Circio.com
- ·8 t sittenInsider trades in Circio 2026. The entire management and board have faith. See attachment.
- ·14 t sitten · MuokattuAvenue Biosciences confirms the collaboration and has made it part of their own strategy Avenue Biosciences has now presented the Circio collaboration on their own website and refers to it as a central project. At the same time, they highlight their recent capital raise of USD 5.7 million, which will be used to scale up their protein engineering platform. Early research collaborations are often announced by only one company. Here we see that both parties actively profile the collaboration, which increases the credibility that both see a real strategic value. This does not change the probability of success in itself, but it strengthens the impression that the collaboration is more than a symbolic press release. https://www.avenuebiosciences.com/press-release/circio-and-avenue-biosciences-jointly-announce-research-collaboration-to-enhance-protein-secretion-for-gene-therapy
- ·1 päivä sittenTHE CALENDAR TOWARDS NEW YEAR — MY READING. 📅🧬 No one knows the dates. But see what's actually in the cards: August 31st — Half-year report. Confirmed date. Full status on pipeline and how the 620 million are used. R&D updates often come here. 📊 September–November — five international conferences in a row. Shanghai, Boston, Phoenix, Hamburg, Cologne. Historically, conferences have been where Circio has presented new data. 🌍 And the milestones themselves, directly from the pipeline — all marked 2H 2026: 🫀 Heart: efficacy data in disease model (first step from reporter gene to real disease) 🧠 CNS: in vivo data from the top-5 collaboration 🧬 In vivo CAR-T: delivery + CAR expression My own guess on the order? The half-year report gives status and direction. The conferences this autumn are natural windows for data. And the CNS reading — the most important of all — points towards Q3/Q4. 🎯 But be clear with yourself: this is MY reading, not a schedule anyone has promised. Biotech slips. Data takes time. It can come later than this. 📉 It can also come faster. No one rings a bell first — remember that the in vivo confirmation in April came on a completely ordinary Friday, without warning. The point is not the date. The point is that the window is open now — and that several independent tracks are maturing into the same period. We know what we own. ♟️🧱🍷
- 1 päivä sittenWhat a week. Time for a couple beers 🍻😊
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
101 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 t sitten · MuokattuCEO Statement: The circVec technology is uniquely positioned with clear differentiation and no direct competitors and will serve as Circio’s platform engine to build and develop enhanced and safer gene and cell therapy medications, both in house and through partnerships. About: Circio is the global leader in vector-based circRNA expression systems with no known competitors with comparable versatility and performance. Circio.com
- ·8 t sittenInsider trades in Circio 2026. The entire management and board have faith. See attachment.
- ·14 t sitten · MuokattuAvenue Biosciences confirms the collaboration and has made it part of their own strategy Avenue Biosciences has now presented the Circio collaboration on their own website and refers to it as a central project. At the same time, they highlight their recent capital raise of USD 5.7 million, which will be used to scale up their protein engineering platform. Early research collaborations are often announced by only one company. Here we see that both parties actively profile the collaboration, which increases the credibility that both see a real strategic value. This does not change the probability of success in itself, but it strengthens the impression that the collaboration is more than a symbolic press release. https://www.avenuebiosciences.com/press-release/circio-and-avenue-biosciences-jointly-announce-research-collaboration-to-enhance-protein-secretion-for-gene-therapy
- ·1 päivä sittenTHE CALENDAR TOWARDS NEW YEAR — MY READING. 📅🧬 No one knows the dates. But see what's actually in the cards: August 31st — Half-year report. Confirmed date. Full status on pipeline and how the 620 million are used. R&D updates often come here. 📊 September–November — five international conferences in a row. Shanghai, Boston, Phoenix, Hamburg, Cologne. Historically, conferences have been where Circio has presented new data. 🌍 And the milestones themselves, directly from the pipeline — all marked 2H 2026: 🫀 Heart: efficacy data in disease model (first step from reporter gene to real disease) 🧠 CNS: in vivo data from the top-5 collaboration 🧬 In vivo CAR-T: delivery + CAR expression My own guess on the order? The half-year report gives status and direction. The conferences this autumn are natural windows for data. And the CNS reading — the most important of all — points towards Q3/Q4. 🎯 But be clear with yourself: this is MY reading, not a schedule anyone has promised. Biotech slips. Data takes time. It can come later than this. 📉 It can also come faster. No one rings a bell first — remember that the in vivo confirmation in April came on a completely ordinary Friday, without warning. The point is not the date. The point is that the window is open now — and that several independent tracks are maturing into the same period. We know what we own. ♟️🧱🍷
- 1 päivä sittenWhat a week. Time for a couple beers 🍻😊
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt